Introduction {#S1}
============

Dementia is related to many underlying pathologies, with Alzheimer's disease (AD) being the most common. AD is pathologically defined by the deposits of two proteins: tau which accumulates intracellularly and β-amyloid that accumulates extracellularly and within the walls of the blood vessels of the central nervous system. Dementia of AD-type is a complex entity with a common clinical syndrome that is likely to be reached by different routes influenced by genetic and environmental factors. This complexity is likely to have contributed to the constant failures of AD clinical trials. In particular, therapies based on the amyloid cascade hypothesis have not demonstrated any disease-modifying effect, despite some of these attempts have been proved to be effective in permanently removing brain β-amyloid plaques ([@B26]). This has led the pharmaceutical industry to focus on other therapeutic targets such as the tau protein ([@B9]).

Neurofibrillary tangles composed of truncated and hyperphosphorylated tau proteins are hallmarks of AD pathology ([@B12]). Tau protein plays an essential role in the central nervous system by promoting microtubule assembly and stability in neuronal cells. Emerging evidence supports that tau function is essential for normal synaptic mechanisms and it may be dysregulated in AD potentially through interaction with genetic risk factors in an Aβ-dependent or Aβ-independent manner ([@B11]). Additionally, tau has been proposed to spread through the brain from neuron to neuron by a "prion-like" mechanism ([@B7]).

Tau protein is encoded by the *MAPT* gene (*MAPT*: OMIM: ^∗^157140), located at chromosome 17q21-22. There are two common *MAPT* extended haplotypes in Caucasians resulting from an ancestral inversion: H1 and H2. The H1 haplotype has been linked with familial and sporadic neurodegenerative disorders like progressive supranuclear palsy (PSP) ([@B8]; [@B5]; [@B14]; [@B27], [@B28]), corticobasal degeneration (CBD) ([@B16]), Frontotemporal Dementia (FTD) ([@B33]), and Parkinson's disease (PD) ([@B21]; [@B32]; [@B28]). Genome-wide association studies (GWAS) have shown that the *MAPT* H1 haplotype is associated with CBD, PSP, and FTD ([@B34]).

The H1 haplotype is further divided into sub-haplotypes, of those H1c has been associated with several neurodegenerative diseases ([@B24]; [@B13]). H1c has been associated with higher levels of tau in plasma and CSF ([@B25]; [@B6]) and inconsistently with AD ([@B24]).

Although recent genetic studies show that several AD GWAS-associated genes, especially BIN1, are potentially involved in tau pathways ([@B11]), *MAPT* itself has not emerged until recently as a locus associated with AD. The IGAP consortium found a significant association between an SNP tagging *MAPT* H1 haplotype (rs2732703) and AD in subjects not carrying APOE ε4, however, the authors concluded that their conditional analysis pointed out that *MAPT* was probably not the causal gene ([@B18]).

Microtubule-associated protein tau H1/H2 haplotype frequency varies according to populations, with H2 frequency being maximum in the Mediterranean region and decreasing gradually as we move away from that area ([@B10]). These differences might contribute to explain controversial results among studies, as genetic stratification in genetically heterogeneous populations might constitute an important confounder. It is therefore essential to study these variants in large genetically homogeneous populations. In a previous study, we showed that H1 *MAPT* haplotype was strongly associated with risk of PSP, PD, and AD in 4435 cases and 6147 controls from Spain ([@B28]). Therefore, it seems that *MAPT* H1/H2 haplotypes might play a relevant role within the genetic architecture of several neurodegenerative pathologies in our country. It is worth mention that the prevalence of the haplotype H2 in our control sample was one of the highest reported worldwide (29%) ([@B28]).

In the present study, we aimed to replicate our previous findings in an independent sample. To do that, we assessed the association between the AD risk and the *MAPT* H1/H2 haplotype and H1 sub-haplotypes in 4,124 AD cases and 3,290 controls from Spain (GR\@ACE/DEGESCO project).

Materials and Methods {#S2}
=====================

A detailed description of the methods and population of the GR\@ACE study has been published elsewhere ([@B22])^[1](#footnote1){ref-type="fn"}^.

Population {#S2.SS1}
----------

The GR\@ACE study comprises 4,120 AD cases and 3,289 control individuals. Cases were recruited from Fundació ACE, Institut Català de Neurociències Aplicades (Barcelona, Spain). Diagnoses were established by a neurology working-group according to the DSM-IV criteria for dementia and to the National Institute on Aging and Alzheimer's Association's (NIA-AA) 2011 guidelines for defining AD. In the present study, we considered AD cases, dementia individuals diagnosed with probable or possible AD at any moment of their clinical course.

Control individuals were recruited from three centers: Fundació ACE (Barcelona, Spain), Valme University Hospital (Seville, Spain) and the Spanish National DNA Bank Carlos III (University of Salamanca, Spain)^[2](#footnote2){ref-type="fn"}^. Written informed consent was obtained from all participants. The Ethics and Scientific Committees have approved this research protocol (Acta 25/2016, Ethics Committee, Hospital Clinic I Provincial de Barcelona, Barcelona, Spain).

Genotyping, Quality Control, Imputation, and Statistical Analysis {#S2.SS2}
-----------------------------------------------------------------

Participants were genotyped using the Axiom 815K Spanish Biobank array (Thermo Fisher). Genotyping was performed in the Spanish National Center for Genotyping (CeGEN, Santiago de Compostela, Spain).

We removed samples with genotype call rates below 97%, excess heterozygosity, duplicates, samples genetically related to other individuals in the cohort or sample mix-up (PIHAT \> 0.1875). If a sex discrepancy was detected, the sample was removed unless the discrepancy was safely resolved. To detect population outliers of non-European ancestry (\>6 SD from European population mean), principal component analysis (PCA) was conducted using SMARTPCA from EIGENSOFT 6.1.4.

We removed variants with a call rate \< 95% or that grossly deviated from Hardy--Weinberg equilibrium in controls (*P*-value ≤ 1 × 10^--4^), markers with a different missing rate between case and control (*P*-value \< 5 × 10^--4^ for the difference) or minor allele frequency (MAF) below 0.01. Imputation was carried out using Haplotype reference consortium (HRC) panel in Michigan Imputation servers^[3](#footnote3){ref-type="fn"}^. Only common markers (MAF \> 0.01) with a high imputation quality (*R*^2^ \> 0.30) were selected to conduct downstream association analyses.

Statistical Analysis {#S2.SS3}
--------------------

Allelic and genotypic frequencies were compared using χ^2^ statistics. Adjusted analyses were performed using multiple logistic regression. We used rs1800547 to tag *MAPT* H2 haplotype. Additionally, we used six tagging variants (rs1467967, rs242557, rs3785883, rs2471738, rs8070723, rs7521), to construct most common *MAPT* H1 sub-haplotypes as previously described ([@B29]; [@B2]). To control for population sub-structure, results were co-variated by the main four principal components detected in this population ([@B22]). All analyses were performed in PLINK 1.7.

Results {#S3}
=======

We included 3290 controls with a mean age of 54.3 ± 14.4 years, and 48.9% of females, and 4124 AD cases with a mean age of 79.0 ± 7.5 years, 69.6% of females. No gross deviation from Hardy Weinberg equilibrium was found in controls for any of the *MAPT* studied variants ([Table 1](#T1){ref-type="table"}).

###### 

Hardy--Weinberg equilibrium test in controls.

  **SNP**     **Genotypes**   **Observed (HET)**   **Expected (HET)**   ***P*-value**
  ----------- --------------- -------------------- -------------------- ---------------
  rs1467967   264/1346/1679   0.41                 0.41                 0.83
  rs242557    346/1426/1517   0.43                 0.44                 0.69
  rs3785883   128/955/2206    0.29                 0.30                 0.06
  rs2471738   89/991/2209     0.30                 0.29                 0.08
  rs8070723   292/1328/1669   0.40                 0.41                 0.24
  rs7521      614/1564/1111   0.48                 0.49                 0.13

[Table 2](#T2){ref-type="table"} shows the allelic and genotypic frequency distribution of the SNPrs1800547 tagging the H1/H2 haplotype. We found a statistically significant overrepresentation of the *MAPT* H1 haplotype, present in 73.3% of AD compared to 71.1% of controls (*p* = 0.00025). When we stratified the sample by *APOE* ε4 status, the association of the H1 haplotype was driven by non-carriers of *APOE* ε4 (*p* = 0.0022) ([Table 2](#T2){ref-type="table"}). The association followed exactly the same pattern as our previous study ([@B28]). Pooling both Spanish population confirmed that *MAPT* H1 was significantly more common in AD compared to controls (73.5 versus 70.7% respectively; *p* = 1.0 × 10^--5^), and this association was predominantly due to the *APOE* ε4 non-carriers (*p* = 8.0 × 10^--5^) ([Table 2](#T2){ref-type="table"}).

###### 

Microtubule-associated protein tau H1/H2 haplotypes and AD risk.

                        **Control (%)**   **AD (%)**     **Genotype *P*-value**   **Allelic *P*-value**   **Allelic OR (95%CI)**
  --------------------- ----------------- -------------- ------------------------ ----------------------- ------------------------
  **ALL**                                                                                                 
  H2H2                  290 (8.8)         328 (8.0)      *p* = 0.008              *p* = 0.00025           1.12 (1.04--1.20)
  H1H2                  1324 (40.2)       1546 (37.5)                                                     
  H1H1                  1676 (50.9)       2250 (54.6)                                                     
  H1 frequency          0.711             0.733                                                           
  **APOE4+**                                                                                              
  H2H2                  58 (8.3)          136 (8.3)      *p* = 0.42               *p* = 0.32              1.07 (0.93--1.23)
  H1H2                  286 (40.7)        625 (37.9)                                                      
  H1H1                  358 (51.0)        887 (53.8)                                                      
  H1 frequency          0.714             0.728                                                           
  **APOE4−**                                                                                              
  H2H2                  232 (9.0)         190 (7.7)      *p* = 0.009              *p* = 0.0022            1.15 (1.05--1.25)
  H1H2                  1033 (40.1)       913 (37.2)                                                      
  H1H1                  1311 (50.9)       1353 (55.1)                                                     
  H1 frequency          0.709             0.737                                                           
  **ALL ([@B28])**                                                                                        
  H2H2                  532 (9.15)        344 (8.34)     *p* = 0.001              *p* = 0.00051           1.12 (1.05--1.19)
  H1H2                  2444 (42.03)      1614 (39.11)                                                    
  H1H1                  2839 (48.82)      2169 (52.56)                                                    
  H1 frequency          0.698             0.721                                                           
  **APOE4+ ([@B28])**                                                                                     
  H2H2                  78 (9.07)         139 (8.50)     *p* = 0.88               *p* = 0.65              1.03 (0.91--1.18)
  H1H2                  345 (40.12)       655 (40.04)                                                     
  H1H1                  437 (50.81)       842 (51.47)                                                     
  H1 frequency          0.709             0.715                                                           
  **APOE4− ([@B28])**                                                                                     
  H2H2                  343 (8.46)        160 (8.16)     *p* = 0.001              *p* = 0.0025            1.14 (1.05--1.24)
  H1H2                  1701 (41.97)      730 (37.24)                                                     
  H1H1                  2009 (49.57)      1070 (54.59)                                                    
  H1 frequency          0.706             0.732                                                           
  **ALL pooled**                                                                                          
  H2H2                  822 (9.0)         672 (8.1)      *p* = 1.03 × 10^--5^     *p* = 1.0 × 10^--5^     1.126 (1.075--1.127)
  H1H2                  3769 (41.4)       3160 (38.3)                                                     
  H1H1                  4515 (49.6)       4419 (53.6)                                                     
  H1 frequency          0.703             0.727                                                           
  **APOE4+ pooled**                                                                                       
  H2H2                  136 (8.7)         275 (8.4)      *p* = 0.52               *p* = 0.286             1.053 (0.958--1.157)
  H1H2                  631 (40.4)        1280 (39.0)                                                     
  H1H1                  795 (50.9)        1729 (52.6)                                                     
  H1 frequency          0.711             0.721                                                           
  **APOE4− pooled**                                                                                       
  H2H2                  575 (8.7)         350 (7.9)      *p* = 5.16 × 10^--5^     *p* = 8.0 × 10^--5^     1.148 (1.08--1.22)
  H1H2                  2734 (41.2)       1643 (37.2)                                                     
  H1H1                  3320 (50.1)       2423 (54.9)                                                     
  H1 frequency          0.707             0.735                                                           

[Table 3](#T3){ref-type="table"} shows the sub-haplotypes of *MAPT* in cases and controls. In addition to the protective effect of H2, only H1c was statistically significantly associated with AD. However, when we adjusted by the four main genetic components H1c was not statistically significant. After stratifying by *APOE* ε4 these results did not change substantially, and in addition to H2, only two rare sub-haplotypes (H1u and H1v) were nominally associated with AD. After adjustment, none of the associations survived multiple comparisons correction ([Table 4](#T4){ref-type="table"}).

###### 

Microtubule-associated protein tau sub-haplotypes.

  **Haplotype ID**   **Haplotype^∗^**   **Cases**   **Controls**   ***P***   **Adjusted *P*-value^∗∗^**
  ------------------ ------------------ ----------- -------------- --------- ----------------------------
  H1o                AAACAA             0.022       0.021          0.63      0.47
  H1y                AAATAG             0.013       0.011          0.31      0.22
  H1d                AAGCAA             0.069       0.072          0.60      0.30
  H1u                AAGCAG             0.025       0.022          0.19      0.14
  H1q                AAGTAA             0.012       0.013          0.52      0.22
  H1c                AAGTAG             0.114       0.104          0.05      0.14
  H1h                AGACAA             0.050       0.047          0.51      0.25
  H1l                AGACAG             0.046       0.044          0.65      0.44
  H1t                AGATAG             0.011       0.010          0.64      0.30
  H1e                AGGCAA             0.075       0.077          0.75      0.90
  H1j                AGGCAG             0.016       0.016          0.78      0.95
  H2                 AGGCGG             0.283       0.309          0.0009    0.0008
  H1z                GAATAG             0.014       0.011          0.12      0.07
  H1i                GAGCAA             0.038       0.040          0.69      0.72
  H1m                GAGCAG             0.026       0.023          0.32      0.36
  H1f                GGACAA             0.014       0.014          0.95      0.75
  H1v                GGATAG             0.014       0.012          0.27      0.08
  H1b                GGGCAA             0.159       0.156          0.60      0.31

∗

rs1467967; rs242557; rs3785883; rs2471738; rs8070723; rs7521;

∗∗

adjusted by the four genetic principal components.

###### 

Microtubule-associated protein tau sub-haplotypes stratified by APOE ε4 status.

  **Haplotype ID**   **Haplotype^∗^**   **OR**   ***P*-value**   **Adjusted *P*-value^∗∗^**
  ------------------ ------------------ -------- --------------- ----------------------------
  **APOE4+**                                                     
  H1o                AAACAA             1.17     0.61            0.63
  H1f                GGACAA             1.55     0.31            0.20
  H1h                AGACAA             0.96     0.81            0.93
  H1i                GAGCAA             1.04     0.83            0.90
  H1d                AAGCAA             0.85     0.26            0.18
  H1b                GGGCAA             1.08     0.43            0.37
  H1e                AGGCAA             1.02     0.88            0.93
  H2                 AGGCGG             0.93     0.28            0.23
  H1z                GAATAG             1.77     0.14            0.10
  H1v                GGATAG             0.95     0.86            0.92
  H1t                AGATAG             1.46     0.37            0.28
  H1c                AAGTAG             1.13     0.27            0.37
  H1l                AGACAG             1.01     0.95            0.64
  H1m                GAGCAG             1.07     0.78            0.89
  H1u                AAGCAG             0.91     0.71            0.76
  H1j                AGGCAG             0.66     0.18            0.21
  **APOE4−**                                                     
  H1q                AAGTAA             1.12     0.56            0.86
  H1g                GAACAA             0.94     0.81            0.92
  H1o                AAACAA             1.12     0.46            0.40
  H1f                GGACAA             0.93     0.74            0.93
  H1h                AGACAA             1.11     0.34            0.19
  H1i                GAGCAA             0.89     0.37            0.46
  H1d                AAGCAA             1.02     0.83            0.83
  H1b                GGGCAA             1.04     0.55            0.34
  H1e                AGGCAA             0.94     0.46            0.90
  H2                 AGGCGG             0.88     0.00            0.00083
  H1z                GAATAG             1.33     0.20            0.24
  H1y                AAATAG             1.30     0.25            0.35
  H1v                GGATAG             1.41     0.13            0.04
  ND                 AGATAG             1.03     0.91            0.65
  H1c                AAGTAG             1.12     0.10            0.37
  H1l                AGACAG             1.06     0.56            0.60
  H1m                GAGCAG             1.21     0.20            0.33
  H1u                AAGCAG             1.41     0.03            0.04
  H1j                AGGCAG             1.15     0.46            0.30

∗

rs1467967; rs242557; rs3785883; rs2471738; rs8070723; rs7521;

∗∗

adjusted by the four genetic principal components.

[Figure 1](#F1){ref-type="fig"} shows the genotypic distribution of the SNP rs1800547 (*MAPT* H1/H2) stratified by *APOE* ε4 across age tertiles for the pooled population. In the available entire sample of 15,522 individuals, we appreciated that within the APOE ε4 non-carriers the association between *MAPT* H1/H2 and AD increased with age, and it was stronger in the oldest individuals.

![Genotype frequency distribution of the rs1800547 SNP tagging *MAPT* H1/H2 haplotype stratified by *APOE* ε4 status and age tertiles.](fnagi-11-00327-g001){#F1}

Discussion {#S4}
==========

Our data, from a large and homogeneous single country population, shows that individuals carrying the H1 *MAPT* haplotype are at higher risk to develop AD dementia. The association is predominantly present in the *APOE* ε4 non-carriers and it is stronger in the eldest. These results replicate our previous findings ([@B28]) and are concordant with the IGAP study ([@B18]) showing an association of another SNP tagging H1 (rs2732703) with AD only in the *APOE* ε4 non-carriers.

Our pooled analysis, including 15522 individuals, strongly support an etiological role of the *MAPT* region in AD. This association has been difficult to replicate, and results of previous studies assessing *MAPT* H1/H2 haplotype as a risk factor for AD have been controversial, although some of them were considerably under-powered ([@B30]; [@B23]; [@B4]). A robust statistical association only emerged in large sample studies and meta-GWAS, after stratifying by *APOE* ε4 ([@B18]; [@B28]). An alternative interpretation of our results would be that the causal variant could be in linkage disequilibrium with the *MAPT* H1 haplotype but outside the *MAPT* gene, as other authors have suggested ([@B18]). A less likely explanation might be contamination of non-AD tauopathies in *APOE* ε4 non-carriers.

There are several factors that might be related to our findings. Taken together, our two studies, comprise one of the largest single-country population assessing *MAPT* H1/H2 and AD risk to date. This is of special value, as the inversion haplotype frequency has been shown to differ significantly across populations, and it is estimated to be 20% in Europeans, 6% in Africans, and less than 1% in East Asians ([@B15]). This ethnic variability might cause population sub-structure biasing the results in countries with a high degree of population admixture. This is likely to be less problematic in our study as our sample come from a single country, and we have tested population sub-structure in Spain which does not represent a substantial problem for common genetic variants analyses ([@B22]). Additionally, in our sub-haplotype analysis, we controlled for population sub-structure by adjusting for genetic principal components. It is worth mentioning that, despite it is commonly reported that the inversion is found at a frequency of around 20% throughout Europe, it shows a great range of frequencies within Europe (from 5 to 37.5%). The H2 haplotype, which identifies the inversion, is most frequent around the Mediterranean decreasing outward in all directions ([@B10]). Our controls presented the inversion in nearly 30% of individuals, this high frequency of the H2 haplotype has increased our power to detect the association compared to other populations in which this variant is less prevalent.

A potential limitation of our study is the age difference between the cases and the controls, which are significantly younger. However, this could only jeopardize the validity of our findings in the case of a survival bias. But to our knowledge, the MAPT H1/H2 haplotype has not been associated with mortality. The most likely consequence of our age unbalance is a decrease in our power to detect the association, as some of the controls carrying the H1 haplotype may still develop AD in the future. It is therefore likely that we are underestimating the true association between the H1/H2 haplotype and AD.

Microtubule-associated protein tau H1 has been associated with many neurodegenerative diseases: PSP, PD, CBD, FTD, and AD. It has been reported that the *MAPT* H1 is more efficient at driving gene expression than the H2 haplotype ([@B20]). This has been shown to be particularly true with the H1c sub-haplotype ([@B25]). However, the H1 sub-haplotype association with AD is controversial, and H1c findings have been difficult to replicate ([@B24]; [@B1]; [@B2]). It is likely that population stratification might have played a role. In our data H1c was nominally associated with AD, however, the statistical significance was lost after adjusting by the principal components supporting the notion that no H1sub-haplotype is specifically increasing AD-risk, and stratification by APOE ε4 did not change substantially these results.

Our results add further evidence for an etiological role of *MAPT* gene variants in clinical AD, supporting the role of the *APOE* ε4 allele as a modulator of this association. As seen in our previous study in population from Spain ([@B28]) and by the international consortium IGAP ([@B18]), this association is significantly stronger in APOE ε4 non-carriers. Recent studies with tau and amyloid PET supports a view of AD as a tauopathy driven by amyloid, suggesting that tau pathology would appear in middle temporal lobe earlier than amyloid deposits, but the co-occurrence of both would be needed for tau pathology to expand beyond the temporal lobes ([@B31]). This is also coherent with the new findings of AD meta-GWAS which shows the involvement of both amyloid and tau pathways ([@B11]; [@B19]). Therefore, it seems that tau and amyloid deposits might follow, at least initially, independent trajectories up to the point when they reach a threshold in which β-amyloid might accelerate tau pathology. A recent single case publication showing that a patient with a presenilin 1 mutation was resistant to cognitive impairment, likely due to a homozygous mutation in *APOE*, supports the hypothesis that *APOE* might play an important role in this tau pathology acceleration ([@B3]). On the other hand, *APOE* status is associated to prevalence of brain amyloid pathology, as shown by a large PET and CSF study in non-demented population that found that *APOE* ε4 carriers had two to three times higher prevalence than non-carriers ([@B17]).

We hypothesize that the *MAPT* H1 variant might increase the risk of tau pathology which might be related to different amyloid thresholds to disparate tau pathology. We speculate that the association is only significant in the *APOE* ε4 non-carriers because in the carriers the amyloid would mask the H1 *MAPT* effect, while in the non-carriers the "tau etiologic pathway" would play a more relevant role and might be able to increase AD risk with a lower amyloid involvement. It is likely that this phenomenon might take longer to develop which might explain why this association is not significant in the youngest patients and stronger in the third tertile. This hypothesis could be tested studying the trajectory of individuals classified according to *APOE* ε4 status and *MAPT* H1/H2 haplotype in prospective cohorts with sequential amyloid and tau PET assessments.

Our study highlights the complexity of AD and suggests the existence of different pathogenic routes influenced by the genetic background. To look for successful therapeutic strategies it will be very important to take into account this mechanistic diversity and to combat specifically the pathology demonstrated on each afflicted individual.
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